Efficacy News and Research

RSS

AMA Task Force to Reduce Opioid Abuse announces national recommendations to address opioid crisis

Opioid abuse is a serious public health problem that has reached crisis levels across the United States, with 44 people dying each day from overdose of opioids, and many more becoming addicted. Recognizing the urgency and serious impact of this issue on the health of hundreds of thousands of patients across the country, today the American Medical Association Task Force to Reduce Opioid Abuse announced the first of several national recommendations to address this growing epidemic.

25 Aug 2015

New study affirms value of influenza vaccination among older people

A new study of the records of millions of nursing home residents affirms the value of influenza vaccination among the elderly. The Brown University analysis found that between 2000 and 2009, the better matched the vaccine was for the influenza strain going around, the fewer nursing home residents died or were hospitalized.

25 Aug 2015

MAT introduces ECO-flow DYNAMIC Screenless UCV Canopy for modern operating theatres

Medical Air Technology (MAT) understands that operating theatres are changing. As technology advances, and the possibilities of what can be achieved within the sterile environment expand, new designs are needed to accommodate new expectations.

25 Aug 2015

Ascendis Pharma's total revenue decreases 50% to €1.9 million in second quarter 2015

Ascendis Pharma A/S, a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced financial results for the three and six months ended June 30, 2015.

25 Aug 2015

High blood sugar may reduce positive effects of exercise on bone health in diabetic patients

Diabetes, which now affects almost 30 million Americans, can cause serious health complications, including heart disease, blindness, kidney failure and lower-extremity amputations.

24 Aug 2015

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

HedgePath Pharmaceuticals, Inc., a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today enrollment has commenced in its Phase II(b) SCORING (SUBA-Cap Objective Response in Gorlin's) clinical trial.

23 Aug 2015

Researchers evaluate use of human fetal progenitor tenocyte to repair tendon injuries

Tendon injuries, especially those acquired while engaging in sports, are not easily healed due to the fibrous nature of tendon tissues which transmit forces from muscle to bone and protect surrounding tissues against tension and compression. Tendon injuries to wrists, knees, elbows and rotator cuffs, often from over use when playing golf or tennis, are increasingly common for both professional and amateur athletes ("weekend warriors") alike.

21 Aug 2015

60P to commence Phase II clinical trial among dengue fever patients

60 Degrees Pharmaceuticals, a company focused on development of therapeutics for tropical diseases, and Singapore General Hospital announced today that the Hospital has received a grant from Singapore's National Medical Research Council to support a Phase II clinical trial among dengue fever patients.

20 Aug 2015

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand.

20 Aug 2015

S1 Biopharma supports FDA's approval of flibanserin for women living with HSDD

S1 Biopharma is a developer of first-in-class drugs for sexual dysfunction in both women and men. The company's lead compound, Lorexys, is currently in Phase IIb for the treatment of hypoactive sexual desire disorder (HSDD).

20 Aug 2015

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Researchers from Memorial Sloan Kettering Cancer Center have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.

20 Aug 2015

Discovery provides new insights into how asthma may be caused

Researchers from the University of Leicester and University Hospitals of Leicester NHS Trust, working with the National Institute of Allergy and Infectious Diseases and Genentech, have discovered new insights into how asthma may be caused, by identifying three distinct groups of asthma patients characterised by the activity of different genes in an individual's airways.

20 Aug 2015

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira today announced that Inflectra (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS).

20 Aug 2015

EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

EnGeneIC Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. The trial is being conducted at the Northern Cancer Institute in Sydney, Australia.

19 Aug 2015

New study compares effectiveness of tinzaparin and warfarin in patients with active cancer, recurrent VTE

Among patients with active cancer and acute symptomatic venous thromboembolism (VTE; blood clots in the deep veins), the use of the low molecular-weight heparin tinzaparin daily for 6 months compared with warfarin did not significantly reduce recurrent VTE and was not associated with reductions in overall death or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding, according to a study in the August 18 issue of JAMA.

19 Aug 2015

Palatin applauds FDA's approval of flibanserin for women living with hypoactive sexual desire disorder

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential. Palatin's lead product under development is bremelanotide for the treatment of female sexual dysfunction (FSD).

19 Aug 2015

MRI scanners can steer cell-based, tumour busting therapies to exact target sites in the body

Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.

19 Aug 2015

Liraglutide drug combined with diet and exercise promotes weight loss in diabetic patients

Among overweight and obese patients with type 2 diabetes, daily injection of the diabetes drug liraglutide with a modified insulin pen device, in addition to diet and exercise, resulted in greater weight loss over 56 weeks compared with placebo, according to a study in the August 18 issue of JAMA.

19 Aug 2015

Intarcia Therapeutics announces positive top-line results from ITCA 650 Phase 3 FREEDOM-2 clinical trial

Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage investigational candidate ITCA 650 to Merck's Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment.

18 Aug 2015

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros Corporation today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body's organs, most commonly the kidney and brain.

18 Aug 2015

Efficacy News and Research

AMA Task Force to Reduce Opioid Abuse announces national recommendations to address opioid crisis

New study affirms value of influenza vaccination among older people

MAT introduces ECO-flow DYNAMIC Screenless UCV Canopy for modern operating theatres

Ascendis Pharma's total revenue decreases 50% to €1.9 million in second quarter 2015

High blood sugar may reduce positive effects of exercise on bone health in diabetic patients

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

Researchers evaluate use of human fetal progenitor tenocyte to repair tendon injuries

60P to commence Phase II clinical trial among dengue fever patients

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

S1 Biopharma supports FDA's approval of flibanserin for women living with HSDD

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Discovery provides new insights into how asthma may be caused

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

New study compares effectiveness of tinzaparin and warfarin in patients with active cancer, recurrent VTE

Palatin applauds FDA's approval of flibanserin for women living with hypoactive sexual desire disorder

MRI scanners can steer cell-based, tumour busting therapies to exact target sites in the body

Liraglutide drug combined with diet and exercise promotes weight loss in diabetic patients

Intarcia Therapeutics announces positive top-line results from ITCA 650 Phase 3 FREEDOM-2 clinical trial

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News